Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Malin Lundkvist"'
Autor:
Marianne G. Dale, Solveig A. Krapf, Tuula A. Nyman, G. Hege Thoresen, Jenny Lund, Eili Tranheim Kase, Malin Lundkvist
Publikováno v:
Pancreatology. 20:676-682
Background /Objectives: We aimed to metabolically compare healthy primary human pancreatic epithelial cells (hPEC) to a pancreatic cancer cell line (PANC-1) and explore the effect on energy metabolism of exposing primary human myotubes to conditioned
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186d73de5569b2774425d8e8b0c4c9bc
https://doi.org/10.1016/j.pan.2020.04.014
https://doi.org/10.1016/j.pan.2020.04.014
Autor:
Jenny Link, Malin Lundkvist Ryner, Katharina Fink, Christina Hermanrud, Izaura Lima, Boel Brynedal, Ingrid Kockum, Jan Hillert, Anna Fogdell-Hahn
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90479 (2014)
A significant proportion of patients with multiple sclerosis who receive interferon beta (IFNβ) therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if HLA class I and II alleles are associated with development of
Externí odkaz:
https://doaj.org/article/5f60c48e706944acad8a48751ad7deb7
Autor:
Anna Fogdell-Hahn, Tomas Olsson, Robert Movérare, Carolina Holmén, Jan Hillert, Elin Engdahl, Malin Lundkvist
Publikováno v:
Multiple Sclerosis Journal. 19:757-764
Background: A small proportion of multiple sclerosis (MS) patients treated with natalizumab develop anti-drug antibodies. Objective: The objective of this paper is to characterize the anti-natalizumab antibody response and to investigate differences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3fff145ddab7803658e889276b85f45
https://doi.org/10.1177/1352458512462920
https://doi.org/10.1177/1352458512462920
Autor:
Roger Jungedal, Elin Engdahl, Jan Hillert, Ryan Ramanujam, Anna Fogdell-Hahn, Ajith Sominanda, Malin Lundkvist, Helga Westerlind
Publikováno v:
Multiple Sclerosis Journal. 18:1775-1781
Background: Neutralizing antibodies (NAbs) against interferon beta (IFNβ) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFNβ during 2003–2004 was 32% in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be739c728a1a475ace81f417229b5eff
https://doi.org/10.1177/1352458512446036
https://doi.org/10.1177/1352458512446036
Autor:
Malin Lundkvist, Anna Fogdell-Hahn, Christian A. Vedeler, Per Soelberg Sørensen, Ralf Gold, Poul Erik Hyldgaard Jensen, Nils Koch-Henriksen, Finn Sellebjerg, Aiden Haghikia, Jan Hillert, Kjell-Morten Myhr
Publikováno v:
Multiple Sclerosis Journal. 17:1074-1078
Background: In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c5a1c6a84d34bc6d7f8f0f2efdfaf2c
https://doi.org/10.1177/1352458511404271
https://doi.org/10.1177/1352458511404271
Autor:
Malin Lundkvist, Charlotte Dahle, Anna Fogdell-Hahn, Jan Hillert, Jan Lycke, Petra Nilsson, Fredrik Piehl, Tomas Olsson, Nils Feltelius, Anders Svenningsson, Elin Karlberg, Carolina Holmén
Publikováno v:
Multiple Sclerosis Journal. 17:708-719
Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010. Methods: Patients were registered in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f351288c89b257e53c9bad795f2eaf
https://doi.org/10.1177/1352458510394701
https://doi.org/10.1177/1352458510394701
Publikováno v:
Multiple Sclerosis Journal. 16:796-800
Multiple sclerosis patients without cerebrospinal fluid oligoclonal IgG bands have been proposed to constitute an immunogenetically distinct subgroup of multiple sclerosis that may also differ in terms of prognosis. A proportion of patients with mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460cbb19cfed7af5aee29129c5a42d74
https://doi.org/10.1177/1352458510373112
https://doi.org/10.1177/1352458510373112
Autor:
Kristina, Bry, Maija, Bry, Elisabet, Hentz, Håkan L, Karlsson, Hanna, Kyllönen, Malin, Lundkvist, Helena, Wigert
Publikováno v:
Acta Paediatrica (Oslo, Norway : 1992)
Aim We quantitatively analysed the effect of a course in communication on the content of nurse–parent encounters and the ability of nurses to respond to the empathic needs of parents in a level III neonatal intensive care unit. Methods We evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::07faa8fdf50fbb48d95c5ca00db247fa
https://pubmed.ncbi.nlm.nih.gov/26648201
https://pubmed.ncbi.nlm.nih.gov/26648201
Autor:
Malin Lundkvist, Elin Engdahl, Ann M. Dring, Iwan Jones, Anders Svenningsson, Thomas Brännström, Jonathan D. Gilthorpe, Anna Fogdell-Hahn
Publikováno v:
Neurology. 80(10)
A 32-year-old woman presented with multiple sclerosis (MS) in 2001, displaying typical MS features on MRI and in the CSF. The patient's clinical condition was relatively stable without major exacerbations on interferon beta-1a but MRI investigation i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865469b8c1f12dc9658e228ff2d7df6d
https://pubmed.ncbi.nlm.nih.gov/23390173
https://pubmed.ncbi.nlm.nih.gov/23390173
Autor:
Anna Fogdell-Hahn, Jan Hillert, Ajith Sominanda, Bernhard Hemmer, Hans-Peter Hartung, Malin Lundkvist, Til Menge, Bernd C. Kieseier
Publikováno v:
Archives of Neurology. 67
Objective To determine if neutralizing antibodies (NAbs) against interferon beta from patients with multiple sclerosis (MS) cross-react with other type 1 interferons, especially endogenous interferon beta, and thus might impede the immune systems of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71006ce9dec4083043f7586bb3413125
https://doi.org/10.1001/archneurol.2010.218
https://doi.org/10.1001/archneurol.2010.218